Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Inclusion Criteria: * Histologic diagnosis of classical, CD30 positive Hodgkin lymphoma confirmed at enrolling institution * FDG-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT * Ann Arbor Stage I or II disease * Disease bulk defined as any lymph node mass with transverse maximal diameter \> 7.0 cm OR coronal maximal diameter \> 7.0 cm on CT imaging * Females of childbearing age must be on an acceptable form of birth control per institutional standards * Ages 18 and over Exclusion Criteria: * Cardiac ejection fraction ≤ 50% * Hemoglobin-adjusted diffusing capacity for carbon monoxide \< 40% * ANC≤1000/μl and Platelets≤75,000/μl * Total bilirubin ≥ 2.0 mg/dl in the absence of a history of Gilbert's disease * Serum creatinine clearance of \<30 mL/min as estimated by the Cockcroft-Gault Method * Known pregnancy or breast-feeding * Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) * Medical illness unrelated to Hodgkin Lymphoma, which, in the opinion of the attending physician and/or MSKCC principal investigator, makes participation in this study inappropriate. * Peripheral neuropathy \> grade 1 * Patients receiving chronic treatment with systemic steroids. However, patients can receive up to 10 days of steroid therapy prior to starting treatment with BV+AVD.